Table 5 shows that, as a group, there are significant differences in expression between non-neoplastic and malignant tumors with a sensitivity of 84.6% for galectin-3 and CK19, and 82.7% for Ret and HBME-1. This evidence concerns the gene KRT19 and cancer.